Mendelian randomization and clinical trial evidence supports TYK2 inhibition as a therapeutic target for autoimmune diseases

BACKGROUND: To explore the associations of genetically proxied TYK2 inhibition with a wide range of disease outcomes and biomarkers to identify therapeutic repurposing opportunities, adverse effects, and biomarkers of efficacy. METHODS: The loss-of-function missense variant rs34536443 in TYK2 gene w...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Shuai, Wang, Lijuan, Zhang, Han, Xu, Fengzhe, Zhou, Xuan, Yu, Lili, Sun, Jing, Chen, Jie, Ying, Haochao, Xu, Xiaolin, Yu, Yongfu, Spiliopoulou, Athina, Shen, Xia, Wilson, Jim, Gill, Dipender, Theodoratou, Evropi, Larsson, Susanna C., Li, Xue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9988426/
https://www.ncbi.nlm.nih.gov/pubmed/36842216
http://dx.doi.org/10.1016/j.ebiom.2023.104488

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9988426/
https://www.ncbi.nlm.nih.gov/pubmed/36842216
http://dx.doi.org/10.1016/j.ebiom.2023.104488

Ejemplares similares